RESUMO
Objective To investigate the clinical efficacy and safety of the combination PP(Pemetrexed+Cisplatin)regimen of sindilizumab(Sintilimab)+bevacizumab(Bevacizumab)in advanced non-squamous non-small cell lung cancer(NSCLC)with disease progression after treatment with epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors.Methods Patients with advanced non-squamous NSCLC with disease progression after receiving EGFR tyrosine kinase inhibitor treatment from January 2019 to January 2022 were retrospectively selected from The Third Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine.According to the different treatment modalities,patients were divided into the pemetrexed+cisplatin treatment group(Chemotherapy)group and the pemetrexed+cisplatin+si ndilizumab+bevacizumab treatment(Sintilimab+Bevacizumab)group.Progression-free survival(PFS),overall survival(OS),objective response rate(ORR)and disease control rate(DCR)were compared between the two groups and the occurrence of adverse reactions was assessed.Results A total of 107 patients were enrolled in the study,53 in the Sintilimab+Bevacizumab group and 54 in the Chemotherapy group.The median PFS and median OS were significantly higher in the Sintilimab+Bevacizumab group than in the Chemotherapy group(P＜0.05).The median PFS and median OS in the Sintilimab+Bevacizumab group were significantly higher than in the Chemotherapy group.Bevacizumab group had no statistically significant difference in ORR with Chemotherapy group(P＞0.05),while DCR was significantly higher than Chemotherapy group(P＜0.05).The main adverse reactions were similar in both groups with the most common adverse events being anemia and neutrophils decrease.Conclusion Sintilimab+Bevacizumab combined with PP regimen treatment improved DCR and prolonged PFS and OS in patients with advanced non-squamous NSCLC whose disease progressed after EGFR tyrosine kinase inhibitor treatment.
RESUMO
Objective To explore the efficacy and safety of Shenqi Fuzheng injection(SFI)combined with docetaxel treatment regime in patients with metastatic castration-resistant prostate cancer(mCRPC).Methods The present studyretrospectively selected mCRP patients diagnosed and treated in the department of urology of Weinan Central Hospital from January 2017 to January 2022 from the electronic medical record system.According to the treatment plan,mCRPC patients were divided into Docetaxel group and Docetaxel+SFI group,receiving docetaxel+prednisone acetate treatment and docetaxel+prednisone acetate+SFI treatment,respectively.The short-term efficacy[objective response rate(ORR)and disease control rate(DCR)]and long-term efficacy[progression free survival(PFS)and overall survival(OS)]of two groups of mCRPC patients were eveluated.The occurrence of adverse reactions during treatment in mCRPC patients was eveluated using were eveluated the common terminology standard for good events(CTCAE 4.03).Results A total of 305 mCRPC patients were included in this study,including 159 cases in Docetaxel+SFI group and 146 cases in Docetaxel group.The ORR and DCR of the Docetaxel+SFI group were significantly higher than those of the Docetaxel group(P＜0.05).The median PFS and median OS of mCRPC patients in the Docetaxel+SFI group were significantly higher than those in the camrelizumab group(P＜0.001).In addition,the incidence of adverse events such as hair loss,diarrhea,nausea and vomiting,anorexia,peripheral edema,and neutropenia in mCRPC patients in the Docetaxel+SFI group was significantly lower than that in the Docetaxel group(P＜0.05).Conclusion Shenqi Fuzheng injection combined with docetaxel has a significant therapeutic effect on mCRP patients,which can improve disease control rate,prolong PFS and OS,and reduce the incidence of adverse reactions.
RESUMO
OBJECTIVE:To explore the necessity of developing therapeutic drug monitoring of vancomycin in our hospital and its existing problems,and provide a reasonable basis for the clinical rational use of vancomycin. METHODS:The cross-sectional survey was designed to collect the clinical data of 92 patients with therapeutic drug monitoring of vancomycin and statistically ana-lyze 192 cases of plasma concentration monitoring data. RESULTS:The average plasma trough concentration was (15.96 ± 8.06) mg/L;with the increase of age,the plasma trough concentration was increasing,there was no significant difference in the plasma trough concentration among different age groups (P=0.000);there were only 13 cases (6.77%) that obtained the plasma trough concentration within 30 min before the fourth dose;after using wancomycin,clearance rates of Cr and the endogenous creatinine were slightly higher than before,but there was no significant difference(P=0.722);36 cases(39.13%)showed vancomycin sus-ceptible gram positive cocci;after using wancomycin,the body temperature,white blood cell count and neutrophil percentage were lower than before,the differences were statistically significant (P=0.006,P=0.000,P=0.000);48 cases (52.17%) in treatment received initial loading dose,and only 15 cases (16.30%) did not use in combination with other anti infective drugs. CONCLU-SIONS:The results showed there are still a lot of problems in the treatment of vancomycin in our hospital,for example,the stan-dard rate of the plasma trough concentration is about 50%;most of the time of blood sampling is not reasonable;the detection rate of the pathogen is low;only about half of the cases are given the loading dose,etc. Therefore clinical pharmacists’intervention for blood sampling is an important part to promote rational drug therapy monitoring. Meanwhile,data interpretation of the monitoring results of serum drug concentration of vancomycin is a basic method for clinical pharmacists in clinical monitoring to correct the un-reasonable operations,and also the necessary measures for preventing the drug renal toxicity,it is a very important significance for the medication safety and effectiveness especially in severe infection patients,the elderly,the children and the people with renal function insufficiency.
RESUMO
Objective To explore the relationship between self efficacy and fall efficacy in patients with stroke.Methods The falls efficacy scale-international (FES-I) and the stroke self-efficacy questionnaire(SSEQ) were applied to 300 patients with stroke.Results The FES-I score of the participants was 39.13± 16.40,the scores of the indoor activity dimension and outdoor activity dimension were (26.01 ± 11.13) and (18.33 ± 7.76),respectively.The total mean score of SSEQ was (40.11 ± 22.37),the scores of the activity function dimension and self-management dimension were (24.97± 14.40)and (15.14±8.35),respectively.FES-I scores were positively correlated with SSEQ scores (r=0.550-0.802,P＜0.05).Falls efficacy could explain 34.3％ and 36.8％ variation amount for each dimension of self-efficacy in patients with stroke.Conclusion Falls efficacy is closely related to self-efficacy in patients with stroke.In order to improve the quality of medical care,medical staff should pay attention to the occurrences of reduction of self-efficacy and selfesteem in patients with stroke when they avoid falling during some activities.